This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

AFH Issues Statement In Response To Its Litigation With Emmaus Life Sciences, Inc.

BEVERLY HILLS, Calif., Jan. 24, 2013 /PRNewswire/ -- AFH Holding & Advisory, LLC, a single member, family office and advisory firm issued the following statement in response to its litigation with Emmaus Life Sciences, Inc.

On December 27, 2012 Los Angeles Superior Court Judge Cesar C. Sarmiento entered a final order preventing Emmaus Life Sciences, Inc. from pursuing a lawsuit it had filed against AFH Holdings, Inc. and its principal Amir Heshmatpour.  AFH Holdings is currently engaged in litigation against Emmaus in Delaware for breach of contract and declaratory relief.

AFH's Suit in Delaware alleges that despite being engaged as the financial advisors to assist Emmaus in becoming a publically traded company, and to assist in further fund raising efforts, Emmaus refused to fully reimburse AFH for expenses incurred therewith.  Additionally, the suit alleges, Emmaus prevented AFH from completing the public offering, and that Emmaus failed to perform its obligations per the parties' agreement.  The suit seeks more than $8.2MM in damages against Emmaus.

In making its Order in Los Angeles, the Court stated that Plaintiff (Emmaus) "seized on an error in the Court's tentative ruling, and is attempting to exploit that error."  The Court found that Emmaus had "failed to make the necessary showing that this action is actually governed by a forum selection clause in a merger agreement, as opposed to the parties' LOIs" (letters of intent).  Those same LOIs are the basis of AFH's litigation against Emmaus in Delaware.

"Regardless of how Emmaus attempted to couch the litigation, it boils down to contract interpretation, and the first step in interpreting the contract is to recognize that there is no basis for a claim here in California" said David Beitchman, AFH's attorney.  "This ruling lends further support to our initial questions regarding the merits and the motives of Emmaus' actions."

About Beitchman & Zekian

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.03 0.21%
FB $116.73 0.00%
GOOG $691.02 0.00%
TSLA $248.99 0.52%
YHOO $36.75 0.44%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs